Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II consolidation study of lenalidomide + alemtuzumab in relapsed/refractory CLL responders
2008-001823-71Phase 2Terminated
- Sponsor
- Associazione Malattie del Sangue
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Associazione Malattie del Sangue. Primary endpoint: Maximum tolerated dose of lenalidomide with alemtuzumab. Started May 2008; status: terminated.
02
Drugs
lenalidomidealemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-001823-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001823-71.